MA31251B1 - Composition pharamceutique - Google Patents

Composition pharamceutique

Info

Publication number
MA31251B1
MA31251B1 MA32218A MA32218A MA31251B1 MA 31251 B1 MA31251 B1 MA 31251B1 MA 32218 A MA32218 A MA 32218A MA 32218 A MA32218 A MA 32218A MA 31251 B1 MA31251 B1 MA 31251B1
Authority
MA
Morocco
Prior art keywords
drug composition
tablet
angiotansin
telmisartan
sorbitol
Prior art date
Application number
MA32218A
Other languages
Arabic (ar)
English (en)
Inventor
Ruediger Thomas
Frieder Maerz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38179677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31251(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA31251B1 publication Critical patent/MA31251B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'objet de la présente invention concerne un comprimé pharmaceutique ou une couche de comprimé contenant de l'angiotansine ii qui est un récepteur antagoniste du telmisartan sous forme amorphe, un agent basique et du sorbitol dont la surface spécifique est comprise entre 0,75 et 3,5 m2/g.
MA32218A 2007-03-14 2009-09-11 Composition pharamceutique MA31251B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104157A EP1970053A1 (fr) 2007-03-14 2007-03-14 Composition pharmaceutique
PCT/EP2008/053009 WO2008110599A1 (fr) 2007-03-14 2008-03-13 Composition pharmaceutique

Publications (1)

Publication Number Publication Date
MA31251B1 true MA31251B1 (fr) 2010-03-01

Family

ID=38179677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32218A MA31251B1 (fr) 2007-03-14 2009-09-11 Composition pharamceutique

Country Status (36)

Country Link
US (1) US20100143465A1 (fr)
EP (2) EP1970053A1 (fr)
JP (1) JP5742045B2 (fr)
KR (1) KR101503674B1 (fr)
CN (1) CN101641084B (fr)
AR (1) AR065726A1 (fr)
AT (1) ATE493119T1 (fr)
AU (1) AU2008225754B2 (fr)
BR (1) BRPI0808797A2 (fr)
CA (1) CA2680608C (fr)
CL (1) CL2008000733A1 (fr)
CO (1) CO6220927A2 (fr)
CY (1) CY1111350T1 (fr)
DE (1) DE602008004217D1 (fr)
DK (1) DK2120884T3 (fr)
EA (1) EA018574B1 (fr)
EC (1) ECSP099629A (fr)
ES (1) ES2358770T3 (fr)
HK (1) HK1140692A1 (fr)
HR (1) HRP20110012T1 (fr)
IL (1) IL200125A (fr)
MA (1) MA31251B1 (fr)
MX (1) MX2009009201A (fr)
MY (1) MY145089A (fr)
NZ (1) NZ580185A (fr)
PE (1) PE20090165A1 (fr)
PL (1) PL2120884T3 (fr)
PT (1) PT2120884E (fr)
RS (1) RS51584B (fr)
SI (1) SI2120884T1 (fr)
TN (1) TN2009000371A1 (fr)
TW (1) TWI406678B (fr)
UA (1) UA96982C2 (fr)
UY (1) UY30961A1 (fr)
WO (1) WO2008110599A1 (fr)
ZA (1) ZA200905224B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (fr) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats
US20100247649A1 (en) * 2007-10-30 2010-09-30 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2009135646A2 (fr) 2008-05-05 2009-11-12 Farmaprojects, Sa Compositions pharmaceutiques stables et procédés de préparation desdites compositions adaptés à l’échelle industrielle
CZ2008469A3 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
GB0822171D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Temisartan formulations
MX346039B (es) 2009-05-20 2017-03-03 Boehringer Ingelheim Vetmedica Gmbh Solucion farmaceutica bebible de telmisartan.
WO2013142314A1 (fr) * 2012-03-19 2013-09-26 Althera Life Sciences, Llc Formulation de comprimé oral constituée de rosuvastatine à libération immédiate et de metformine à libération prolongée
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
WO2015119289A1 (fr) * 2014-02-10 2015-08-13 富士フイルム株式会社 Comprimé orodispersible
BE1021954B1 (nl) * 2014-06-05 2016-01-28 Syral Belgium Nv Samenstelling van sorbitol met lage friabiliteit
FR3023128B1 (fr) 2014-07-01 2017-11-10 Roquette Freres Nouvelle composition edulcorante
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN109316451B (zh) * 2017-07-31 2022-07-01 武汉朗来科技发展有限公司 治疗高血压和相关疾病的口服固体制剂
SG11202010792TA (en) 2018-05-02 2020-11-27 Ferring Bv Improved pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245170A1 (de) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
AU1042199A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Antihypertensive medicaments containing lacidipine and telmisartan
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
PT1467712E (pt) * 2002-01-16 2008-01-09 Boehringer Ingelheim Pharma Comprimido farmacêutico de duas camadas compreendendo telmisartan e hidroclorotiazida
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
SI1814527T1 (sl) * 2004-11-05 2014-03-31 Boehringer Ingelheim International Gmbh Dvoslojna tableta, ki obsega telmisartan in amlodipin
AU2005315855A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy

Also Published As

Publication number Publication date
WO2008110599A1 (fr) 2008-09-18
ZA200905224B (en) 2010-04-28
UY30961A1 (es) 2008-10-31
CO6220927A2 (es) 2010-11-19
TW200900095A (en) 2009-01-01
PE20090165A1 (es) 2009-03-31
DE602008004217D1 (de) 2011-02-10
KR20090119998A (ko) 2009-11-23
HRP20110012T1 (hr) 2011-02-28
MY145089A (en) 2011-12-30
TN2009000371A1 (fr) 2010-12-31
CY1111350T1 (el) 2015-08-05
PT2120884E (pt) 2011-02-10
US20100143465A1 (en) 2010-06-10
SI2120884T1 (sl) 2011-04-29
CN101641084A (zh) 2010-02-03
ATE493119T1 (de) 2011-01-15
AU2008225754A1 (en) 2008-09-18
AR065726A1 (es) 2009-06-24
AU2008225754B2 (en) 2013-04-04
CL2008000733A1 (es) 2008-07-04
BRPI0808797A2 (pt) 2013-01-15
DK2120884T3 (da) 2011-02-07
HK1140692A1 (en) 2010-10-22
EP2120884B1 (fr) 2010-12-29
IL200125A0 (en) 2010-04-15
EP2120884A1 (fr) 2009-11-25
EA018574B1 (ru) 2013-09-30
JP5742045B2 (ja) 2015-07-01
ECSP099629A (es) 2009-10-30
UA96982C2 (ru) 2011-12-26
CN101641084B (zh) 2013-04-10
RS51584B (en) 2011-08-31
KR101503674B1 (ko) 2015-03-18
JP2010530844A (ja) 2010-09-16
ES2358770T3 (es) 2011-05-13
TWI406678B (zh) 2013-09-01
EP1970053A1 (fr) 2008-09-17
MX2009009201A (es) 2009-09-08
PL2120884T3 (pl) 2011-05-31
IL200125A (en) 2012-01-31
CA2680608A1 (fr) 2008-09-18
NZ580185A (en) 2011-11-25
CA2680608C (fr) 2015-06-16
EA200901169A1 (ru) 2010-04-30

Similar Documents

Publication Publication Date Title
MA31251B1 (fr) Composition pharamceutique
TNSN08313A1 (fr) Des formes pharmaceutiques resistantes a la modification
PE20080151A1 (es) Formulaciones farmaceuticas de fenilefrina y composiciones para su absorcion en el colon
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
EA200501586A1 (ru) Фармацевтические продукты
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
AR076540A1 (es) Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de analgesicos no- opioides y opioides, forma de dosificacion. metodo de preparacion. metodo para tratar dolor
ME01532B (me) Jedinjenja
WO2007016563A3 (fr) Formulations pharmaceutiques resistantes a l'alcool
FR14C0020I1 (fr) Compositions pharmaceutiques contenant du fentanyl pour application nasale
WO2008021851A3 (fr) Nouveaux composés comme antagonistes ou agonistes inverses pour les récepteurs d'opioïdes
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
HK1120442A1 (en) Novel opioid antagonists
CL2013001885A1 (es) Compuestos derivados de morfina, antagonistas del receptor ipiode periferico; composicion farmaceutica; formulacion oral; y uso para reducir los efectos colaterales de la terapia opioide (div. sol. 905-08).
NI201000104A (es) SALES FARMACEUTICAMENTE ACEPTABLES DE (3-{[[3-(6-AMINO-2-BUTOXI-8- 0X0-7,8-DIHIDRO-9H-PURIN-9-lL) PROPIL] (3-MORFOLIN-4-lLPROPIL) AMINOWETIL} FENIL) ACETATO DE METILO Y SUS USOS EN TERAPIA.
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
DK1899334T3 (da) Naphthyridinforbindelser
CL2008003615A1 (es) Composicion farmaceutica transmucosal oral que comprende fenilefrina, o una sal de ella, que esta en forma de tiras, de capa bioadhesiva, de liquido para pulverizar, de pastilla , de gel, de capsulas o de tableta; dispositivo portador.
CO6150122A2 (es) Comprimidos pediatricos de capecitabina
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
FR2912915B1 (fr) Film a desintegration rapide pour l'administration buccale de substances actives.
MA28526B1 (fr) Comprimes solubles contenant licarbazepine
CL2007003110A1 (es) Compuestos derivados de ciclohexilamida, moduladores de los receptores de serotonina 5-ht2a y dopamina d3; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento y/o prevencion de trastornos cognitivos, adiccion a las drogas, depresi